12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD.

Committed to Safeguarding Vision and Enhancing Lives

Ocular Therapeutix is a biopharmaceutical company developing transformational treatments that enhance people’s vision and quality of life through consistent and sustainable drug delivery.

Our Technology Press Releases

Retinal Diseases

inner eye

THERAPEUTIC AREAS

Retinal Diseases

Researching preservative-free, sustained-release implants to replace the need for repeated injections

Glaucoma

Doctor Checking Patient's Eyes

THERAPEUTIC AREAS

Glaucoma

Researching biodegradable hydrogel alternative to the lifelong burden of daily eye drops

Ocular Surface Diseases

lab staff

THERAPEUTIC AREAS

Ocular Surface Diseases

Researching sustained-release inserts to provide lasting treatment without preservatives for dry eye disease

Ophthalmic Surgery

Ophthalmic Surgery

THERAPEUTIC AREAS

Ophthalmic Surgery

Ongoing investigation of innovative ELUTYX^TM technology to transform treatments in postoperative care

Hyrdro

ELUTYX™ Technology

Our Elutyx technology is a versatile platform employed to create sustained-release therapies that may expand treatment options across multiple ocular conditions.

Helpful Resources

Events & Presentations

Learn more about Ocular Therapeutix at upcoming events and corporate presentations

Scientific & Medical Presentations

Read the latest scientific and medical presentations on Ocular Therapeutix emerging therapies

Find answers to commonly asked questions about Ocular Therapeutix

blue eye fibers

Ocular Therapeutix is growing quickly. We offer exciting career opportunities and comprehensive benefits for talented candidates.

See All Open Positions

Careers at Ocular

September 6, 2023

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update

Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results

Ocular Therapeutix™ Announces Appointment of New Board Member

Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD

Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting

Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference